|
|
 |
|
¡¡ |
|
¡¡ |
|
|
|
¡¡ |
HOME > ÇÐȸ°£Ç๰ >
¿ë¾î»çÀü |
|
Á¦¸ñ |
Studies on Circulating Immune Complex and Leukocyte Migration Inhibitory Factor in Leprosy Patients |
|
|
|
|
ÀúÀÚ |
Joo Young Park, In Hong Choi, Se Jong Kim, Joon Lew, Joo Deuk Kim |
¼Ò¼Ó |
Dept. of Microbiology Yonsei University College of Medicine, World Vision Special |
|
|
³âµµ |
1984 |
±Ç |
17 |
|
|
È£ |
1 |
¹øÈ£ |
|
|
|
½ÃÀÛÆäÀÌÁö |
93 |
³¡ÆäÀÌÁö |
103 |
|
|
÷ºÎ |
|
|
|
¿ä¾à |
Lepromatous leprosy is characterized by extensive bacillary invasion, a high level of circulating immune complexes of Mycobacterium leprae and a marked impairment of specific T cell mediated immunity (Bjorvatn et al, 1976; Bullock, 1978). With increasing burden of M. leprae or infection, i.e. moving to polar lepromatous form, there is a decrease in cell mediated immunity; reduced in vitro response to phytohemagglutinin (PHA) (Han et al, 1974) and M. leprae (Dierk and Shepard, 1965), and reduced delayed hypersensitivity reaction to lepromin or dinitrichlorobenzene (DNCB) (Waldorf et al. 1966). In the others hand, circulating immune complexes are thought to be responsible for tissue lesions in lepromatous leprosy, particularly iota those in erythema nodosum leprosum (ENL). In the present study, circulating immune complexes by polyethylene glycol-complement consumption(PEG-CC) test and leukocyte migration inhibitory factor (LIF) production by PHA-stimulated peripheral blood lymphocytes in leprosy patients was detected. Furthermore we also have attempted to test whether HLA-linked gene acts as a genetic marker for responding and clearing M. leprae antigen and immune complex. In conclusion: 1. Circulating immune complexes are significantly increased in the sera from lepromatous leprosy and tuberculoid leprosy compared to normal controls. However there are no significant differences between the level of circulating immune complexes in the sera from lepromatous leprosy patients and that from tuberculoid leprosy patients. 2. Circulating immune complexes in the sera from lepromatous leprosy patients with ENL or neuralgia are significantly increased. 3. It is suggested that circulating immune complexes in the sera from lepromatous leprosy patients are decreased after bacteriologically negative conversion by the treatment, but not significant. 4. There is no correlation between HLA-DR2, DR4 or DRw9 antigens and circulating immune complexes in leprosy patients. 5. With PHA stimulation, the leukocyte migration indices were 70.5¡¾18.8 in lepromatous leprosy, 56.0¡¾15.4 in tuberculoid leprosy and 57.0¡¾13.9 in healthy control group. LIF production is significantly impaired in leprosy, particularly in circulating immune complex positive leprosy patients.(p<0.05) It is conclude4 that in lepromatous leprosy, circulating immune complexes in sera are increased, but the production of LIF by peripheral blood lymphocytes with stimulation of PHA is impaired. |
|
|
³»¿ë |
|
 | |
¡¡ |
|
|
|
|
|
|
|
|